Search
Nimotop尼膜同

Nimotop

nimodipine

Manufacturer:

Bayer

Distributor:

Zuellig
/
Firma Chun Cheong
Concise Prescribing Info
Contents
Nimodipine
Indications/Uses
Prevention (tab) & treatment (infusion) of ischaemic neurological deficit following aneurysmal subarachnoid haemorrhage.
Click to view Nimotop detailed prescribing information
Dosage/Direction for Use
Tab Adult Prophylaxis 2 tab 4-hrly (360 mg daily). Start w/in 4 days of subarachnoid haemorrhage onset & continued for 21 days. Infusion Treatment Start infusion w/ 1 mg/hr (about 15 mcg/kg/hr) for 2 hr. Increase dose to 2 mg/hr (about 30 mcg/kg/hr) after the 2nd hr. Begin treatment as early as possible after neurological deficit, continue for at least 5 days up to a max of 14 days. Patients weighing <70 kg or w/ unstable BP Start dose w/ 0.5 mg/hr or less if necessary.
Click to view Nimotop detailed prescribing information
Overdosage
View Nimotop overdosage for action to be taken in the event of an overdose.
Administration
May be taken with or without food: Take consistently, either always w/ or always w/o meals. Swallow whole, do not chew/crush.
Contraindications
Hypersensitivity. Tab: Concomitant administration w/ rifampicin; antiepileptic drugs (eg, phenobarb, phenytoin or carbamazepine).
Click to view Nimotop detailed prescribing information
Special Precautions
Close monitoring is recommended in case of elevated intracranial pressure or generalized cerebral edema. Use cautiously in patients w/ hypotension. Patients w/ unstable angina or w/in 1st 4 wk after acute MI. May impair sperm function. Pregnancy & lactation. Tab: Co-administration w/ CYP3A4 inhibitors & inducers. Infusion: Contains 23.7% ethanol.
Click to view Nimotop detailed prescribing information
Adverse Reactions
Thrombocytopenia; allergic reaction, rash; headache; tachycardia; hypotension, vasodilatation; nausea. Infusion: Inj & infusion site reactions (eg, thrombophlebitis).
Click to view Nimotop detailed prescribing information
Drug Interactions
Increased plasma conc w/ fluoxetine. Slightly decreased exposure w/ nortriptyline. Increased effects of anti-hypertensives [eg, diuretics, β-blockers, ACE inhibitors, other Ca antagonists, α-adrenergic blocking agents (eg, α1-antagonists), PDE5 inhibitors, α-methyldopa]. Tab: Reduced efficacy w/ rifampicin. Reduced bioavailability w/ CYP3A4-inducing anti-epileptic drugs (eg, phenobarb, phenytoin or carbamazepine). Potential increased plasma conc w/ macrolide antibiotics (eg, erythromycin); anti-HIV PIs (eg, ritonavir); azole anti-mycotics (eg, ketoconazole); nefazodone; quinupristin/dalfopristin; cimetidine; valproic acid; grapefruit juice. Infusion: Mutual potentiation of negative ionotropic action w/ simultaneous IV administration of β-blockers. Renal function deterioration w/ aminoglycosides, cephalosporins, furosemide. Increased AUC of zidovudine IV.
Click to view Nimotop detailed prescribing information
Caution For Usage
For caution against possible variation of physical aspect of medicine... Click to view Nimotop detailed prescribing information
Storage
View Nimotop storage conditions for details to ensure optimal shelf-life.
Description
View Nimotop description for details of the chemical structure and excipients (inactive components).
Action
View Nimotop mechanism of action for pharmacodynamics and pharmacokinetics details.
ATC Classification
C08CA06 - nimodipine ; Belongs to the class of dihydropyridine derivative selective calcium-channel blockers with mainly vascular effects. Used in the treatment of cardiovascular diseases.
Presentation/Packing
Form
Nimotop tab 30 mg
Packing/Price
30's
Form
Nimotop infusion solution 10 mg/50 mL
Packing/Price
5 × 1's
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $768 a year.
Sign up for free
Already a member? Sign in